The deal brings SAI — a key distributor serving pharmaceutical and nutraceutical manufacturers — into the Safic-Alcan Group’s expanding Asia footprint
The acquisition gives Bayer full rights to PER-001, an experimental therapy now in Phase II clinical trials for Glaucoma and Diabetic Retinopathy
Conceptualized as an aggregator platform it integrates existing programme systems through an API-based federated architecture
While Drugs for Neglected Diseases initiative (DNDi) drives the R&D for neglected diseases, we collaborate with pharmaceutical companies at multiple stages, including sourcing promising molecules
Both join the leading CRDMO’s executive committee to drive global people strategy and commercial expansion
Certification reinforces energy efficiency, sustainability goals, and green manufacturing across SMT’s Surat and Hyderabad facilities
Our company is prioritising deeper collaborations with CDMOs and biosimilar companies as part of its strategy to expand its footprint across India, Middle East, and Africa region
Angelique Kruif brings over 20 years of HR leadership built across a range of international organisations
The collaboration underscores a broader industry shift toward hybrid research models that integrate computational biology with advanced experimental systems
Together, the companies aim to deliver an integrated toolkit for biomarker discovery and clinical research
Subscribe To Our Newsletter & Stay Updated
